PEB 2 3 2004 U

INFOR	MAT	ION DIS	SCLOS	URE CI	TATION	AT	ATTY. DOCKET NO. PC25082A SERIAL NO. 10/734,411								
INFORMATION DISCLOSURE CITATION RADE (Use several sheets if necessary)							APPLICANT Matthew F. Brown, et al.								
									December 12, 2003 GROUP						
						U.S	. PATEN	T DOC	UMENTS						
EXAMINER INITIAL		DOCUMENT NUMBE							DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
Ao	US	3	1	1	9	7	4	2	01/28/64	Heimlich et al.		167	82		
AO	us	3	4	9	2	3	9	7	01/27/70	Peters et al.		424	20		
AD	US	3	5	3	8	2.	1	4	11/03/70	Polli et al.		424	19		
10	US	4	0	6	0	5	9	8	11/29/77	Groppenbacher et al		424	33		_
Ao	US	4	1	. 7	3	6	2	6	11/06/79	Dempski et al		424	19		
					·F	ORE	IGN PAT	ENT DO	DCUMEN.	TS					
DOCUMENT NUMBER									DATE	COUNTRY		CLASS	SUBCLASS	TRANSLA	
														YES	NO
,													_		
			ОТН	ER DO	CUMENT	S (In	cluding A	uthor, 1	itle, Date,	Pertinent Pa	ges, E	Etc.)			
Au		Combadiere, Christophe, et al., "Monocyte Chemoattractant Protein-3 Is a Functional Ligand for CC Chemokine Receptors 1 and 2B", The Journal of Biological Chemistry, Vol. 270, No. 50, 29671-29675 (1995)													
		Teran, Luis M., et al., "Eosinophil Recruitment Following Allergen Challenge Is Associated with the Release of the Chemokine RANTES into Asthmatic Airways", The Journal of Immunology, 157:1806-1812 (1996)													
		Smith, Robert E., et al., "Production and Function of Murine Macrophage Inflammatory Protein-1a in Belomycin-Induced Lung Injury", The Journal of Immunology, 153:4704 (1994).													
		Maryanoff, Bruce E., et al., "Stereochemistry of the Wittig Reaction. Effect of Nucleophilic Groups in the Phosphonium Ylide", J. Am. Chem.Soc., 107, 217-226 (1985)													
		Berge, Stephen M., et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, Vol. 66, No. 1, 1-19 (1977)													
		Cook, Donald N., et al., "Requirement of MIP-1a for an Inflammatory Response to Viral Infection", Science, Vol. 269, 1583-1585 (1995)													
DO		Kuna, and A	Piotr, et symptom	al., "Stud atic Subj	ies of MCAF	/MCP	-1, RANTES	S, MIP-1 : Absract	alpha, IL-8, i 321, January	nistamine, ECP a y 1994.	nd Try	ptase in A	llergic Rhini	is Suffer	rers
EXAMINE	R A	n. l	ر		the s	n	<u></u>	DATE C	ONSIDERE	D /	3/	m	J		
EXAMINER I	initial if re cation to	eference con applicant.	sidered, who	ether or not o	citation is in con	formano	e with MPEP 60	9; Draw line	through citation	if not in conformance	and not o	considered, in	clude copy of th	is form with	,

Conforms with FORM PTO-FB-A820

July 2 1 2005 Co.

INFORMATION DISCLOSURE CITATION ATTY. DOCKET NO. PC25082A SERIAL NO. 10/734,411 (Use several sheets if necessary) APPLICANT Matthew F. Brown, et al. FILING DATE December 12, 2003 **GROUP** 1752 **U.S. PATENT DOCUMENTS** FILING DATE EXAMINER INITIAL CLASS SUBCLASS DOCUMENT NUMBER NAME US 4 8 2 2 7 8 0 4/18/89 Tsuda, Yoshiaki, et 514 119 al. FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION NO wo 0 5 01/22/98 International 9 8 2 1 1 wo 9 8 5 6 12/17/98 International wo 0 7 2 7 2 10/04/01 Intetrnational 1 8 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) DATE CONSIDERED **EXAMINER** EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

INFORMATION DISCLOSURE CITATION LIST.DOT, 9/99